Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors
Pediatric Drugs · 2024
DOI: 10.1007/s40272-024-00624-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Drugs, 2024. Verfasst von Iris K Minichmayr und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Bevacizumab, Brain Neoplasms, Neoplasm Recurrence, Local, Angiogenesis Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Forschungsgesellschaft für Cerebrale Tumore, Medical University of Vienna.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: To date, evidence has been lacking regarding bevacizumab pharmacokinetics in the cerebrospinal fluid (CSF). OBJECTIVE: This study assessed the penetration of bevacizumab, as part of a metronomic antiangiogenic treatment regimen, into the CSF of children, adolescents, and young adults with recurrent brain tumors. PATIENTS AND METHODS: Serum and CSF concentrations, malignant cells, and vascular endothelial growth factor A (VEGF-A) were analyzed in 12 patients (5-27 years) following 10 mg/kg bevacizumab intravenous biweekly administration (EudraCT number 2009-013024-23). A population pharmacokinetic model including body weight, albumin, and tumor type as influential factors was extended to quantify the CSF penetration of bevacizumab. RESULTS: Apart from in serum (minimum concentration/maximum concentration [Cmin/Cmax] 77.0-305/267-612 mg/L, median 144/417 mg/L), bevacizumab could be quantified in the CSF (0.01-2.26 mg/L, median 0.35 mg/L). The CSF/serum ratio was 0.16 and highly variable between patients. Malignant cells could be detected in CSF before initiation of treatment in five of 12 patients; after treatment, the CSF was cleared in all patients. VEGF-A was detected in three patients before treatment (mean ± SD: 20 ± 11 pg/mL), and was still measurable in one of these patients despite treatment (16 pg/mL). CONCLUSIONS: This pharmacokinetic pilot study indicated penetration of bevacizumab into the CSF in a population of children, adolescents, and young adults with recurrent brain tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
- Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria.
- Department of Neurology, Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria.
- Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. andreas.peyrl@meduniwien.ac.at.
- Comprehensive Center for Pediatrics, Medical University of Vienna, Vienna, Austria. andreas.peyrl@meduniwien.ac.at.
Förderung
- Forschungsgesellschaft für Cerebrale Tumore
- Medical University of Vienna
Zitieren
APA
Minichmayr, I. K., Knaack, U., Gojo, J., Senfter, D., Haberler, C., Azizi, A. A., Mayr, L., Zeitlinger, M., & Peyrl, A. (2024). Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors. Pediatric Drugs. https://doi.org/10.1007/s40272-024-00624-y
Vancouver
Minichmayr IK, Knaack U, Gojo J, Senfter D, Haberler C, Azizi AA, et al. Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors. Pediatric Drugs. 2024. doi:10.1007/s40272-024-00624-y
BibTeX
@article{Minichmayr2024,
author = {Minichmayr, Iris K and Knaack, Ursula and Gojo, Johannes and Senfter, Daniel and Haberler, Christine and Azizi, Amedeo A and Mayr, Lisa and Zeitlinger, Markus and Peyrl, Andreas},
title = {Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors},
journal = {Pediatric Drugs},
year = {2024},
doi = {10.1007/s40272-024-00624-y}
}
EUVIMED